|
| 骨硬化蛋白抗体治疗骨质疏松症的研究进展 |
| Research progress in the treatment of osteoporosis with scleroprotein antibodies |
| |
| DOI：10.3969/j.issn.1006-7108.2025.08.021 |
| 中文关键词: 骨质疏松 Wnt/β-catenin信号通路 骨形成 骨硬化蛋白抗体 |
| 英文关键词:osteoporosis Wnt/β-catenin signaling pathway bone formation sclerostin monoclonal antibody |
| 基金项目:陕西省自然科学基础研究计划(S2018-JC-YB-1870) |
|
| 摘要点击次数: 213 |
| 全文下载次数: 0 |
| 中文摘要: |
| Wnt/β-连环蛋白(β-catenin)信号通路通过调节成骨细胞分化在骨形成中起重要作用，而骨细胞产生的硬化蛋白能拮抗Wnt/β-catenin信号的传导，抑制骨形成。骨硬化蛋白抗体（sclerostin monoclonal antibody，Scl-Ab）作为近年来新的抗骨质疏松(osteoporosis，OP)药物，可以刺激骨形成，增加骨量和骨强度，减少骨吸收，为OP治疗带来新的希望。该文结合近年来国内外相关文献对该类药物的作用机制、临床疗效与不良反应等进行综述，旨在为防治OP提供参考。 |
| 英文摘要: |
| Wnt/β-catenin (β-catenin) signaling pathway plays an important role in bone formation by regulating osteoblast differentiation. Scleroprotein produced by osteocytes antagonizes the conduction of Wnt/β-catenin signaling and inhibits bone formation. As a new anti-osteoporosis (OP) drug in recent years, sclerostin monoclonal antibody (Scl-Ab) stimulates bone formation, increases bone mass and strength, reduces bone resorption, and brings new hope for OP treatment. This article reviews the mechanism of action, clinical efficacy, and adverse reactions of these drugs based on relevant literature at home and abroad in recent years, aiming to provide a reference for the prevention and treatment of OP. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |